Intussusception Risk after Rotavirus Vaccination in U.S. Infants

    Basic Details
    Date
    Thursday, February 6, 2014
    Type
    Publication
    Medical Product
    Rotarix
    RotaTeq
    rotavirus vaccine
    Health Outcome(s)
    intussusception
    Description

    This article describes the findings of a study conducted to evaluate the risk of intussusception associated with two Rotavirus vaccines, Rotateq (RV5) and Rotarix (RV1), in infants 5 to 30.9 weeks of age in the United States. 

    Information
    Time Period
    2004–2011
    Population / Cohort
    All infants 5 to 30.9 weeks of age
    Data Source(s)
    Mini-Sentinel Distributed Database (MSDD)
    Author(s)

    W. Katherine Yih PhD, MPH; Tracy A. Lieu MD, MPH; Martin Kulldorff PhD; David Martin MD, MPH; Cheryl McMahill-Walraven PhD, MSW; Richard Platt MD, MSc; Nandini Selvam PhD, MPH; Mano Selvan PhD; Grace M. Lee MD, MPH; Michael Nguyen MD

    Corresponding Author

    W. K. Yih, Department of Population Medicine, Harvard Pilgrim Healthcare Institute and Harvard Medical School, 401 Park Drive, Suite 401 East, Boston, MA 02215, U.S.A. E-Mail: katherine_yih@harvardpilgrim.org